Ornithine Transcarbamylase (OTC) Deficiency

Definition And Genetics

The most common urea cycle disorder, characterized by the inability to convert ornithine and carbamoyl phosphate into citrulline.
Inherited in an X-linked recessive manner, making it the only X-linked urea cycle disorder, while all others are autosomal recessive.
Incidence ranges from approximately 1 in 14,000 to 1 in 77,000 live births.
Caused by mutations in the OTC gene located at chromosome Xp11.4.
Males present as hemizygotes with a severe, neonatal-onset phenotype, while heterozygous females have a variable phenotype ranging from asymptomatic to fatal due to skewed X-inactivation (Lyonization).

The primary defect is a deficiency of the hepatic mitochondrial enzyme ornithine transcarbamylase, which leads to distinct metabolic consequences.

Metabolic Consequence	Mechanism And Effects
Hyperammonemia	Failure to detoxify ammonia into urea leads to severe neurotoxicity, cerebral edema, and astrocyte swelling.
Orotic Aciduria	Accumulated carbamoyl phosphate shunts into the pyrimidine synthesis pathway, generating excess orotic acid.
Amino Acid Imbalance	Depletion of downstream citrulline and arginine, rendering arginine an essential amino acid.

Infants typically appear healthy at birth but develop symptoms after 24â€“48 hours upon initiation of protein feeding.
Presents as a sepsis mimic with poor feeding, lethargy, vomiting, and hypothermia.
Neurologic manifestations include central hyperventilation secondary to cerebral edema, which causes a classic respiratory alkalosis.
Rapidly progresses to somnolence, seizures, deep coma, and a bulging fontanelle from increased intracranial pressure.

Symptoms are often triggered by a high protein load, catabolic stress such as infection or surgery, postpartum stress, or valproate use.
Patients may have a history of voluntary protein aversion, recurrent vomiting, and failure to thrive.
Episodic presentations include ataxia, confusion, aggression, irritability, and psychiatric manifestations.
Cyclical vomiting or migraine-like headaches are also common.

Diagnostic workup relies on identifying the specific biochemical abnormalities and confirming the genetic defect.

Investigation Type	Findings And Significance
Initial Screening	Plasma ammonia is markedly elevated (>150â€“200 Âµmol/L, often >1000 in neonates). Arterial blood gas shows respiratory alkalosis, which differentiates it from the metabolic acidosis seen in organic acidemias.
Plasma Amino Acids	Demonstrates low or absent citrulline, low arginine, and high glutamine (which acts as ammonia storage).
Urine Organic Acids	Markedly elevated orotic acid. This finding is critical to distinguish OTC deficiency from carbamoyl phosphate synthetase 1 deficiency, where orotic acid is low or normal.
Confirmatory Tests	Molecular genetics via OTC gene sequencing is the standard of care. Liver biopsy for enzyme assay is rarely needed.
Carrier Detection	An allopurinol challenge test can be used to detect carrier females by inducing orotic aciduria.

Stop nitrogen intake by suspending all natural dietary protein for a maximum of 24â€“48 hours.
Reverse catabolism by administering high-calorie intravenous fluids (10â€“20% dextrose with lipids) to suppress endogenous protein breakdown.
Initiate ammonia scavenging pharmacotherapy using intravenous sodium phenylacetate and sodium benzoate to conjugate glutamine and glycine for urinary excretion.
Administer intravenous arginine or citrulline to prime the functional portions of the urea cycle and prevent catabolism.
Hemodialysis or continuous renal replacement therapy is mandated if ammonia exceeds 500 Âµmol/L or if the patient fails medical therapy.

Maintain a severely protein-restricted diet combined with essential amino acid supplements.
Prescribe oral nitrogen scavengers, such as sodium benzoate, phenylbutyrate, or glycerol phenylbutyrate.
Provide lifelong supplementation with L-citrulline or L-arginine.
Liver transplantation is curative for the metabolic defect and is usually performed between 6 months and 1 year of age to prevent further neurocognitive damage, though it does not reverse pre-existing brain damage.

Neonatal-onset disease carries high mortality, and survivors often suffer from significant developmental delay and intellectual disability, which is inversely proportional to the duration of the neonatal coma.
Late-onset disease has a better prognosis if recognized and treated early, though the risk of hyperammonemia crises remains a lifelong threat.